Predictive Oncology (POAI) announced today the company has successfully developed 3D organoid models exclusively for Labcorp (LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing agreement, Predictive Oncology recently developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, including a human and rat model. Both models represent the liver microenvironment and can be used for the evaluation of both drug metabolism and liver toxicity related to drugs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on POAI:
- Predictive Oncology Faces Nasdaq Delisting Notice
- Predictive Oncology says court denies Renovaro motion for expedited trial
- Renovaro announces expedited trial on suit to enforce Predictive Oncology merger
- Predictive Oncology moves to leverage biobank using AI
- Predictive Oncology issued shareholder letter